<DOC>
	<DOCNO>NCT01534078</DOCNO>
	<brief_summary>Brentuximab antibody-drug conjugate ( ADC ) , combination antibody ( protein bind cell ) chemotherapy molecule . Brentuximab work use antibody portion enter Hodgkin lymphoma cell release chemotherapy portion , attempt destroy cell . The intravenous chemotherapy drug Adriamycin , Vinblastine Dacarbazine ( AVD ) receive research study approve use people Hodgkin Lymphoma . A drug call bleomycin usually include AVD , since appear less effective drug significant potential risk , replace study drug brentuximab . In research study , investigator look see whether brentuximab combination AVD effective treat limited-stage Hodgkin Lymphoma .</brief_summary>
	<brief_title>Brentuximab Vedotin Plus AVD Limited-stage Hodgkin Lymphoma</brief_title>
	<detailed_description>Each treatment cycle 28 day . You receive brentuximab alone Day 1 15 first cycle ( lead-in cycle ) . After cycle 1 , receive brentuximab combine AVD Day 1 15 4-6 cycle , depend response therapy . Brentuximab AVD give intravenous infusion ( IV ) . The following test procedure perform Days 1 15 cycle : - Review side effect experience medication take - Performance Status - Physical exam vital sign - Routine blood test - Questionnaire evaluate symptom neuropathy - Research blood sample look marker see body respond study medication - PET-CT scan prior complete cycle 2 combination brentuximab/AVD After final dose study drug : The following assessment perform within one month last dose study medication : - Review side effect experience medication take - Performance Status - Physical exam vital sign - Routine blood test - Questionnaire evaluate symptom neuropathy - Research blood sample look marker see body respond study medication - PET-CT scan Follow include follow - Review side effect experience medication take - Performance Status - Review Physical exam - Routine blood test - Questionnaire evaluate symptom neuropathy - CT scan</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previously untreated stage IA , IB , IIA IIB classical Hodgkin Lymphoma Nonbulky disease define less 10 cm maximal diameter Measurable disease great equal 1.5 cm ECOG performance status 0 2 Willing use 2 effective form birth control No prior chemotherapy radiotherapy Hodgkin lymphoma Not receive investigational agent No history allergic reaction attribute compound similar chemical biologic composition Adriamycin , Vinblastine , Dacarbazine brentuximab No preexist grade 3 great neuropathy No uncontrolled intercurrent illness Not pregnant breastfeed No history different malignancy unless disease free least one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>non-bulky</keyword>
	<keyword>limited stage</keyword>
</DOC>